Kos Pharmaceuticals and Takeda Pharmaceuticals reach agreement to co-promote Niaspan and Advicor

Share this article:

Kos Pharmaceuticals and Takeda Pharmaceuticals have reached a three-year agreement to co-promote Kos' Niaspan and Advicor in the U.S. market. The agreement adds more than 1,000 Takeda sales representatives to the existing Kos sales force to detail the two products developed by Kos for treating cholesterol disorders. The increased promotional effort is expected to significantly enhance the value of Kos' cholesterol franchise within the U.S., the largest cholesterol market in the world. For Takeda, the agreement fills current sales force capacity while allowing the company to continue to grow its franchise product, Actos.

The co-promotion arrangement has a three-year term commencing January 2004 and provides for residual payments to Takeda after the three years, if the parties do not renew the agreement.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.